A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects

Journal of Clinical Pharmacology

Volumn 37, Issue 9, 1997, Pages 799-809

  Salazar, Daniel E ^a   Much, David R ^a   Nichola, Peter S ^a   Seibold, James R ^b   Shindler, Daniel ^b   Slugg, Peter H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOTALOL;

ADULT; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE;

EID: 0030869429     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb05627.x     Document Type: Article

References (16)

1. Woosley RL, Hohnloser SH: Sotalol. N Engl J Med 1994; 331:31-38.
2. Brown HC, Carruthers SG, Kelly JG, McDevitt DG, Shanks RG: Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol 1976;9:367-372.
3. Gomall AW, Bartek MJ: Comparative β-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs. Eur J Pharmacol 132;1986:123-135.
4. Yasuda SA, Barbey JT, Funck-Brentano C, Wellstein A, Woosley RL: d-Sotalol reduces heart rate in vivo through a β-adrenergic receptor-independent mechanism. Clin Pharmacol Ther 1993; 53:436-442.
5. Zehender M, Hohnloser S, Just H: QT interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. Cardiovasc Drug Ther 1991;5:515-530.
6. Thomas SHL: Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React Toxicol Rev 1994;13(2):77-102.
7. McComb JM, McGovern B, McGowar JB, Ruskin JN, Garan H: Electrophysiologic effects of d-sotalol in humans. J Am Cardiol 1987;10:211-217.
8. Le Coz F, Funck-Bretano C, Poirier JM, Kibleur Y, Mazoit FX, Jaillon P: Prediction of sotalol-induced maximum steady-state QTc prolongation from single-dose administration in healthy volunteers. Clin Pharmacol Ther 1992;51:417-426.
9. D'Argenio DZ, Schumitzky A: ADAPT II Users Guide. Los Angeles: Biomedical Simulations Resource, University Of California, Los Angeles, 1992.
10. Jusko WJ: Conceptualization of drug distribution to a hypothetical pharmacodynamic effect compartment. Clin Pharmacol Ther 1994;54:112-113.
11. Holford NHG, Sheiner LB: Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981;6:429-453.
12. Hill AV: The possible effects of the aggregation of the molecules of hemoglobin on the dissociation curves. J Physiol 1910;40:iv-vii.
13. Uematsu T, Kanamaru M, Nakashima M: Comparative pharmacokinetic and pharmacodynamic properties of oral and intraveous (+)-sotalol in healthy volunteers. J Pharm Pharmacol 1994; 46:600-605.
14. Rautaharju PM, Zhou SH, Wong S, Calhoun HP, Berenson GS, Prineas R, Davignon A: Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992; 8:690-695.
15. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
16. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pitt B, et al: Effect of d-sotalol on mortality in patients with lett ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.